GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Pharmaceutical Group Co Ltd (SHSE:600664) » Definitions » Financial Strength

Harbin Pharmaceutical Group Co (SHSE:600664) Financial Strength : 6 (As of Mar. 2025)


View and export this data going back to 1993. Start your Free Trial

What is Harbin Pharmaceutical Group Co Financial Strength?

Harbin Pharmaceutical Group Co has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Harbin Pharmaceutical Group Co's Interest Coverage for the quarter that ended in Mar. 2025 was 27.22. Harbin Pharmaceutical Group Co's debt to revenue ratio for the quarter that ended in Mar. 2025 was 0.08. As of today, Harbin Pharmaceutical Group Co's Altman Z-Score is 2.64.


Competitive Comparison of Harbin Pharmaceutical Group Co's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Pharmaceutical Group Co's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Harbin Pharmaceutical Group Co's Financial Strength falls into.


;
;

Harbin Pharmaceutical Group Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Harbin Pharmaceutical Group Co's Interest Expense for the months ended in Mar. 2025 was ¥-11 Mil. Its Operating Income for the months ended in Mar. 2025 was ¥287 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥65 Mil.

Harbin Pharmaceutical Group Co's Interest Coverage for the quarter that ended in Mar. 2025 is

Interest Coverage=-1*Operating Income (Q: Mar. 2025 )/Interest Expense (Q: Mar. 2025 )
=-1*286.68/-10.533
=27.22

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Harbin Pharmaceutical Group Co's Debt to Revenue Ratio for the quarter that ended in Mar. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1289.499 + 65.476) / 16697.696
=0.08

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Harbin Pharmaceutical Group Co has a Z-score of 2.64, indicating it is in Grey Zones. This implies that Harbin Pharmaceutical Group Co is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.64 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Pharmaceutical Group Co  (SHSE:600664) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Harbin Pharmaceutical Group Co has the Financial Strength Rank of 6.


Harbin Pharmaceutical Group Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Harbin Pharmaceutical Group Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
Xi'an Street West, People 's Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
Executives
Liu Bo senior management
Xia Ji Cheng senior management
Qiu Fang Ju Supervisors
Li Bang Dong senior management
Jiang Hai Tao senior management
Meng Xiao Dong senior management
Lin Guo Ren senior management
Wang Hai Sheng senior management
Xu Hai Ying Directors, senior managers
Liang Chen senior management
Wang Peng Hao senior management
Xiao Qiang senior management
Bian Ke Supervisors
Zhou Xing senior management
Wei Shuang Ying senior management

Harbin Pharmaceutical Group Co Headlines

No Headlines